GlassScriptPhysician profile
Azin Azma
NPI 1669632154
$1,624.02
in general payments reported to CMS, 2019-2025
13 companies · $138 in 2025
The $138 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $646 · 2023: $215 · 2024: $624 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $978.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $978.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $445.28 | 2019-2025 | Briviact |
| Medtronic Vascular, INC. | $220.12 | 2019 | |
| Abbvie INC. | $164.93 | 2023-2024 | Ubrelvy |
| E.R. Squibb & Sons, L.L.C. | $145.86 | 2024 | Sotyktu |
| Genentech USA, INC. | $124.99 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $121.15 | 2024 | Saphnelo |
| Novo Nordisk INC | $117.91 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $102.79 | 2024 | Libtayo |
| Boston Scientific Corporation | $100.00 | 2019 | |
| Emd Serono, INC. | $25.00 | 2023 | Mavenclad |
| Philips North America LLC | $20.19 | 2023 | |
| Ns Pharma, INC. | $18.01 | 2025 | Viltepso |
| Celgene Corporation | $17.79 | 2023 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Azin Azma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.